Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
Would you use trastuzumab with chemotherapy in a patient with metastatic gastric cancer that is HER2 negative but ERBB3 positive?
Would you use this combination in frontline vs later lines of therapy ?
Answer from: Medical Oncologist at Academic Institution
No, there are clearly no validated data for this and I do not have any anecdotal experience to suggest benefit.
Such a patient should be referred for studies of pan-ErBB inhibitors, e.g. afatinib or neratinib.
Sign in or Register to read more